Smith & Nephew is trading 6.3% down today at £1122.00 after the company lowered its full-year revenue guidance despite maintaining its profit and cash-flow targets.
- The outlook revision follows slower revenue growth in the first half, specifically impacted by softer U.S. Orthopaedics performance and pressure in Advanced Wound Bioactives.
- The move extends a reversal from a recent sentiment-driven rebound as investors focus on fundamental operational challenges highlighted in the August 4 results.